BLS Pharmaceuticals（BLS）株式概要BLS Pharmaceuticals Limitedは、その子会社とともに、オーストラリア、米国、英国、チェコ共和国、および日本で、医薬品および健康・ウェルネス関連製品を製造・販売しています。 詳細BLS ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績5/6財務の健全性5/6配当金0/6報酬株価収益率（ 24.2 x）は、 Life Sciences業界平均（ 37.8 x）を下回っています。過去1年間で収益は244.8%増加しました リスク分析高いレベルの非現金収入 すべてのリスクチェックを見るBLS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW471,746 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA471,746 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$0.9487.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-13m612m2016201920222025202620282031Revenue AU$611.6mEarnings AU$113.8mAdvancedSet Fair ValueView all narrativesBLS Pharmaceuticals Limited 競合他社CryositeSymbol: ASX:CTEMarket cap: AU$61.0mAroa BiosurgerySymbol: ASX:ARXMarket cap: AU$207.5mVita Life SciencesSymbol: ASX:VLSMarket cap: AU$133.2mClinuvel PharmaceuticalsSymbol: ASX:CUVMarket cap: AU$481.6m価格と性能株価の高値、安値、推移の概要BLS Pharmaceuticals過去の株価現在の株価AU$0.9452週高値AU$1.1052週安値AU$0.33ベータ0.621ヶ月の変化-0.53%3ヶ月変化13.25%1年変化77.36%3年間の変化487.50%5年間の変化193.75%IPOからの変化-50.53%最新ニュースお知らせ • Jul 28BLS Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Aug 26, 2026BLS Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Aug 26, 2026New Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).分析記事 • Apr 14If EPS Growth Is Important To You, Bioxyne (ASX:BXN) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Recent Insider Transactions • Mar 24CEO, MD & Executive Director recently bought AU$90k worth of stockOn the 19th of March, Samuel Watson bought around 2m shares on-market at roughly AU$0.05 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Samuel's only on-market trade for the last 12 months.最新情報をもっと見るRecent updatesお知らせ • Jul 28BLS Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Aug 26, 2026BLS Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Aug 26, 2026New Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).分析記事 • Apr 14If EPS Growth Is Important To You, Bioxyne (ASX:BXN) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Recent Insider Transactions • Mar 24CEO, MD & Executive Director recently bought AU$90k worth of stockOn the 19th of March, Samuel Watson bought around 2m shares on-market at roughly AU$0.05 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Samuel's only on-market trade for the last 12 months.New Risk • Feb 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 87% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Market cap is less than US$100m (AU$134.4m market cap, or US$95.6m).分析記事 • Feb 13Why Investors Shouldn't Be Surprised By Bioxyne Limited's (ASX:BXN) 30% Share Price SurgeBioxyne Limited ( ASX:BXN ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Dec 16Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 28Bioxyne Limited, Annual General Meeting, Nov 26, 2025Bioxyne Limited, Annual General Meeting, Nov 26, 2025. Location: at addisons level 9, 2 park street, sydney nsw 2000 AustraliaReported Earnings • Oct 05Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024)Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$29.3m (up 204% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 17% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.分析記事 • Sep 22What You Can Learn From Bioxyne Limited's (ASX:BXN) P/S After Its 31% Share Price CrashBioxyne Limited ( ASX:BXN ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...Reported Earnings • Aug 31Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024)Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$30.4m (up 216% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 16% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Aug 08Bioxyne Limited (ASX:BXN) Stocks Shoot Up 28% But Its P/S Still Looks ReasonableDespite an already strong run, Bioxyne Limited ( ASX:BXN ) shares have been powering on, with a gain of 28% in the last...お知らせ • Jul 23Bioxyne Limited to Report Q4, 2025 Results on Jul 28, 2025Bioxyne Limited announced that they will report Q4, 2025 results on Jul 28, 2025分析記事 • Jun 18Bioxyne Limited (ASX:BXN) Stocks Shoot Up 38% But Its P/S Still Looks ReasonableBioxyne Limited ( ASX:BXN ) shareholders would be excited to see that the share price has had a great month, posting a...Buy Or Sell Opportunity • May 07Now 29% overvaluedOver the last 90 days, the stock has fallen 33% to AU$0.026. The fair value is estimated to be AU$0.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable.分析記事 • Apr 28Bioxyne Limited's (ASX:BXN) Share Price Is Still Matching Investor Opinion Despite 26% SlumpThe Bioxyne Limited ( ASX:BXN ) share price has fared very poorly over the last month, falling by a substantial 26%. Of...Buy Or Sell Opportunity • Apr 15Now 21% overvaluedOver the last 90 days, the stock has fallen 14% to AU$0.025. The fair value is estimated to be AU$0.021, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable.お知らせ • Apr 03Bioxyne Limited Appoints Michael Barnes to Its Advisory BoardBioxyne Limited (BXN) announced that leading consultant neurologist, Professor Michael Barnes MD. FRCP ("Mike" or "Prof Barnes"), president of the Cannabis Industry Council, president of the Medical Cannabis Clinicians Society (UK) has joined the BXN advisory board. Prof Barnes will advise the Company as it develops its medicinal cannabis business in the UK. Prof Barnes was previously an advisor to GW Pharmaceuticals. The Company will also leverage Prof Barnes's experience in registering medicines for marketing authorization, which will allow it to distribute its products through traditional prescriber channels, without the need for special access or authorized prescriber pathways. Author of more than a dozen authoritative books and 100 academic papers, Prof. Barnes has dedicated the latter part of his career to the development of medical cannabis awareness, education and clinical excellence. He brings his expertise to global medical cannabis organisations, educates clinicians and patients and advocates for a pragmatic and robust approach to medical cannabis prescribing as the UK industry growth. In 2018, Prof. Barnes was the first UK doctor to successfully negotiate a medical cannabis prescription from the Government, for Alfie Dingley. Prof Barnes was the Founder Chair of the Medical Cannabis Clinicians Society, a not-for-profit society providing training, expert guidance & peer support for clinicians prescribing life- changing medical cannabis treatments in the UK. He also is chair of the Cannabis Industry Council. As Honorary President of the Cannabis Industry Council and the Medical Cannabis Clinicians Society, Mike is connected with every medical cannabis prescriber and clinic in the UK. He also advises government on legislation relating to the medical cannabis industry. As a consultant neurologist and medical cannabis expert, Professor Mike Barnes has dedicated his career to the development of neurological rehabilitation and medical cannabis treatments and education. Over 30 years within senior roles in the NHS and independent neurorehabilitation services, Professor Barnes became interested in the medical applications of cannabis with the progression of Sativex to market. He signed off an expert report to the Medicines and Healthcare products Regulatory Agency which was subsequently used, with more recent evidence, to establish Sativex - a cannabis extract which alleviates symptoms of multiple sclerosis - in over 30 countries.お知らせ • Mar 21Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct ListingBuy Or Sell Opportunity • Mar 14Now 35% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to AU$0.027. The fair value is estimated to be AU$0.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable.分析記事 • Mar 11Bioxyne Limited (ASX:BXN) Shares Slammed 46% But Getting In Cheap Might Be Difficult RegardlessThe Bioxyne Limited ( ASX:BXN ) share price has softened a substantial 46% over the previous 30 days, handing back much...お知らせ • Jan 23Bioxyne Limited Upgrades Revenue Guidance for the Year Ended 30 June 2025Bioxyne Limited advised that its upgraded Revenue forecast for the year ended 30 June 2025 is increased to $25,000,000.お知らせ • Oct 04Bioxyne Limited, Annual General Meeting, Nov 21, 2024Bioxyne Limited, Annual General Meeting, Nov 21, 2024.Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.64m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.66m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.お知らせ • Apr 23Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listingお知らせ • Apr 18Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct ListingNew Risk • Apr 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Market cap is less than US$10m (AU$15.2m market cap, or US$9.86m).お知らせ • Nov 17Bioxyne Limited Announces Retirement of N H Chua as DirectorBioxyne Limited announced that Mr. N H Chua has retired from the Board following the Annual General Meeting that was held 17 November 2023. Sam Watson will continue as sole Chief Executive Officer and Managing Director.お知らせ • Oct 05Bioxyne Limited, Annual General Meeting, Nov 17, 2023Bioxyne Limited, Annual General Meeting, Nov 17, 2023, at 10:00 AUS Eastern Standard Time.Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)Full year 2023 results: AU$0.001 loss per share (in line with FY 2022). Revenue: AU$5.30m (up AU$4.84m from FY 2022). Net loss: AU$1.94m (loss widened 293% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0.002 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0.002. Revenue: AU$5.34m (up 115% from FY 2022). Net loss: AU$1.94m (loss widened AU$1.70m from FY 2022).New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$2.3m revenue, or US$1.5m). Market cap is less than US$100m (AU$22.8m market cap, or US$14.6m).お知らせ • May 24Bioxyne Limited Appoints Jason Hine as DirectorBioxyne Limited announced that the appointment of Jason Hine as director of the company with effect from May 19, 2023.お知らせ • May 23Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd.Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals. On March 20, 2023, Bioxyne executed the long form Sale and Purchase Agreement with BLS’ majority shareholders. Completed due diligence confirms the synergies between the Bioxyne and BLS. The Bioxyne and BLS have commenced formulating a combined business development growth strategy for post-acquisition. Other conditions precedent to completion include, The remaining minority BLS shareholders acceding as parties to the SPA, New employment agreements for key BLS employees, including appropriate restraints and No material adverse change occurring in relation to Breathe Life Sciences. BXN and BLS will work together, in good faith, to satisfy the remaining conditions precedent by May 31, 2023 to implement the proposed transaction. If the conditions precedent are not satisfied (or waived) by this date, then unless the Long Stop Date is extended by agreement, either party may terminate the SPA and the proposed transaction. As of May 5, 2023, Bioxyne received shareholder approval for the acquisition of BLS.Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd on May 22, 2022. Bioxyne has completed the acquisition of Breathe Life Sciences following shareholder approval, due diligence and the satisfaction of all conditions precedent. BLS's Sam Watson (Chief Executive Officer) and Jason Hine (Chief Operating Officer) will be appointed to the Board of Directors.Reported Earnings • Feb 24First half 2023 earnings releasedFirst half 2023 results: Revenue: AU$1.28m (down 9.9% from 1H 2022). Net income: AU$23.2k (up 409% from 1H 2022). Profit margin: 1.8% (up from 0.3% in 1H 2022). The increase in margin was driven by lower expenses.お知らせ • Dec 21Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals.お知らせ • Dec 20Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive OfficerBioxyne Limited announced joining of Mr. Sam Watson the board as Joint Chief Executive Officer.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 24Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million.Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million on October 24, 2022. The Direct Selling business comprises of Bioxyne International Pty Limited, Bioxyne International (NZ) Limited, Bioxyne International Sdn Bhd, PT Gamata Utama, Global Treasure New Zealand Limited and New Zealand Nutritional Research Limited.お知らせ • Oct 04Bioxyne Limited, Annual General Meeting, Oct 28, 2022Bioxyne Limited, Annual General Meeting, Oct 28, 2022, at 14:00 AUS Eastern Standard Time.Reported Earnings • Oct 02Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)Full year 2022 results: EPS: AU$0 (improved from AU$0.001 loss in FY 2021). Revenue: AU$2.48m (up 13% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 31Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)Full year 2022 results: EPS: AU$0 (up from AU$0.001 loss in FY 2021). Revenue: AU$2.52m (up 14% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Board Change • Jun 24No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Jun 08Bioxyne Limited Announces Board ChangesBioxyne Limited announced that Mr. Patrick Ford, after serving the company as a director for 17 years, including as chairman of thecompany between 2008 and 2012, has advised the board that Patrick will retire on 30 June 2022. Mr. Guy Robertson, company secretary, will be appointed an executive director, on 30 June 2022. Mr. Robertson is a chartered accountant and is currently a director of Hastings Technology Metals Ltd, Artemis Resources Limited, Metal Bank Limited and Greentech Metals Limited. Ms Rachel Qian, the group's financial controller, will be appointed assistant company secretary, with effectfrom 30 June 2022. Ms Qian has a B.Com, master of accounting (Macquarie), is CPA qualified and is member of the Governance Institute of Australia.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0 (up from AU$0.001 loss in 1H 2021). Revenue: AU$1.42m (up 13% from 1H 2021). Net income: AU$4.6k (up AU$289.2k from 1H 2021). Profit margin: 0.3% (up from net loss in 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 04Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.20m (down 5.6% from FY 2020). Net loss: AU$495.7k (loss narrowed 16% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.22m (down 4.3% from FY 2020). Net loss: AU$425.7k (loss narrowed 28% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Oct 03Full year earnings released - AU$0.00093 loss per shareOver the last 12 months the company has reported total losses of AU$593.1k, with losses narrowing by 53% from the prior year. Total revenue was AU$2.32m over the last 12 months, up 5.4% from the prior year.株主還元BLSAU Life SciencesAU 市場7D3.3%7.1%-0.7%1Y77.4%23.0%2.4%株主還元を見る業界別リターン: BLS過去 1 年間で23 % の収益を上げたAustralian Life Sciences業界を上回りました。リターン対市場: BLS過去 1 年間で2.4 % の収益を上げたAustralian市場を上回りました。価格変動Is BLS's price volatile compared to industry and market?BLS volatilityBLS Average Weekly Movement11.5%Life Sciences Industry Average Movement17.3%Market Average Movement9.7%10% most volatile stocks in AU Market16.8%10% least volatile stocks in AU Market3.9%安定した株価: BLS 、 Australian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: BLSの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1998n/aSam Watsonblspharma.comBLS Pharmaceuticals Limitedは、子会社とともに、オーストラリア、米国、英国、チェコ共和国、および日本で、医薬品および健康・ウェルネス関連製品を製造・販売しています。 同社は、「Dr Watson」および「PCC」ブランドの下で、医療用大麻、MDMA、サイロシビン、処方薬、プロバイオティクス、NAD、および一般向け健康製品を提供しています。また、治験薬および向精神薬向けに、医薬品の製造、卸売、流通、輸入、輸出、および受託製造サービスも提供しています。 同社は、認可を受けたクリニック、薬局、卸売業者、栽培業者、医薬品有効成分メーカー、および医薬品ブランドスポンサーにサービスを提供している。同社は以前はBioxyne Limitedという名称であったが、2026年6月にBLS Pharmaceuticals Limitedに社名を変更した。BLS Pharmaceuticals Limitedは1998年に設立され、オーストラリアのシドニーに本社を置いている。もっと見るBLS Pharmaceuticals Limited 基礎のまとめBLS Pharmaceuticals の収益と売上を時価総額と比較するとどうか。BLS 基礎統計学時価総額AU$217.33m収益（TTM）AU$8.92m売上高(TTM)AU$47.95m24.2xPER（株価収益率4.5xP/SレシオBLS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BLS 損益計算書（TTM）収益AU$47.95m売上原価AU$28.27m売上総利益AU$19.69mその他の費用AU$10.77m収益AU$8.92m直近の収益報告Dec 31, 2025次回決算日Aug 26, 2026一株当たり利益（EPS）0.039グロス・マージン41.05%純利益率18.60%有利子負債／自己資本比率13.6%BLS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/14 15:41終値2026/08/14 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BLS Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 28BLS Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Aug 26, 2026BLS Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Aug 26, 2026
New Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).
お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
分析記事 • Apr 14If EPS Growth Is Important To You, Bioxyne (ASX:BXN) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Recent Insider Transactions • Mar 24CEO, MD & Executive Director recently bought AU$90k worth of stockOn the 19th of March, Samuel Watson bought around 2m shares on-market at roughly AU$0.05 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Samuel's only on-market trade for the last 12 months.
お知らせ • Jul 28BLS Pharmaceuticals Limited to Report Fiscal Year 2026 Results on Aug 26, 2026BLS Pharmaceuticals Limited announced that they will report fiscal year 2026 results on Aug 26, 2026
New Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).
お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
分析記事 • Apr 14If EPS Growth Is Important To You, Bioxyne (ASX:BXN) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Recent Insider Transactions • Mar 24CEO, MD & Executive Director recently bought AU$90k worth of stockOn the 19th of March, Samuel Watson bought around 2m shares on-market at roughly AU$0.05 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Samuel's only on-market trade for the last 12 months.
New Risk • Feb 27New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 87% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Market cap is less than US$100m (AU$134.4m market cap, or US$95.6m).
分析記事 • Feb 13Why Investors Shouldn't Be Surprised By Bioxyne Limited's (ASX:BXN) 30% Share Price SurgeBioxyne Limited ( ASX:BXN ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...
お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Dec 16Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 28Bioxyne Limited, Annual General Meeting, Nov 26, 2025Bioxyne Limited, Annual General Meeting, Nov 26, 2025. Location: at addisons level 9, 2 park street, sydney nsw 2000 Australia
Reported Earnings • Oct 05Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024)Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$29.3m (up 204% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 17% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
分析記事 • Sep 22What You Can Learn From Bioxyne Limited's (ASX:BXN) P/S After Its 31% Share Price CrashBioxyne Limited ( ASX:BXN ) shares have retraced a considerable 31% in the last month, reversing a fair amount of their...
Reported Earnings • Aug 31Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024)Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$30.4m (up 216% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 16% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Aug 08Bioxyne Limited (ASX:BXN) Stocks Shoot Up 28% But Its P/S Still Looks ReasonableDespite an already strong run, Bioxyne Limited ( ASX:BXN ) shares have been powering on, with a gain of 28% in the last...
お知らせ • Jul 23Bioxyne Limited to Report Q4, 2025 Results on Jul 28, 2025Bioxyne Limited announced that they will report Q4, 2025 results on Jul 28, 2025
分析記事 • Jun 18Bioxyne Limited (ASX:BXN) Stocks Shoot Up 38% But Its P/S Still Looks ReasonableBioxyne Limited ( ASX:BXN ) shareholders would be excited to see that the share price has had a great month, posting a...
Buy Or Sell Opportunity • May 07Now 29% overvaluedOver the last 90 days, the stock has fallen 33% to AU$0.026. The fair value is estimated to be AU$0.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable.
分析記事 • Apr 28Bioxyne Limited's (ASX:BXN) Share Price Is Still Matching Investor Opinion Despite 26% SlumpThe Bioxyne Limited ( ASX:BXN ) share price has fared very poorly over the last month, falling by a substantial 26%. Of...
Buy Or Sell Opportunity • Apr 15Now 21% overvaluedOver the last 90 days, the stock has fallen 14% to AU$0.025. The fair value is estimated to be AU$0.021, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable.
お知らせ • Apr 03Bioxyne Limited Appoints Michael Barnes to Its Advisory BoardBioxyne Limited (BXN) announced that leading consultant neurologist, Professor Michael Barnes MD. FRCP ("Mike" or "Prof Barnes"), president of the Cannabis Industry Council, president of the Medical Cannabis Clinicians Society (UK) has joined the BXN advisory board. Prof Barnes will advise the Company as it develops its medicinal cannabis business in the UK. Prof Barnes was previously an advisor to GW Pharmaceuticals. The Company will also leverage Prof Barnes's experience in registering medicines for marketing authorization, which will allow it to distribute its products through traditional prescriber channels, without the need for special access or authorized prescriber pathways. Author of more than a dozen authoritative books and 100 academic papers, Prof. Barnes has dedicated the latter part of his career to the development of medical cannabis awareness, education and clinical excellence. He brings his expertise to global medical cannabis organisations, educates clinicians and patients and advocates for a pragmatic and robust approach to medical cannabis prescribing as the UK industry growth. In 2018, Prof. Barnes was the first UK doctor to successfully negotiate a medical cannabis prescription from the Government, for Alfie Dingley. Prof Barnes was the Founder Chair of the Medical Cannabis Clinicians Society, a not-for-profit society providing training, expert guidance & peer support for clinicians prescribing life- changing medical cannabis treatments in the UK. He also is chair of the Cannabis Industry Council. As Honorary President of the Cannabis Industry Council and the Medical Cannabis Clinicians Society, Mike is connected with every medical cannabis prescriber and clinic in the UK. He also advises government on legislation relating to the medical cannabis industry. As a consultant neurologist and medical cannabis expert, Professor Mike Barnes has dedicated his career to the development of neurological rehabilitation and medical cannabis treatments and education. Over 30 years within senior roles in the NHS and independent neurorehabilitation services, Professor Barnes became interested in the medical applications of cannabis with the progression of Sativex to market. He signed off an expert report to the Medicines and Healthcare products Regulatory Agency which was subsequently used, with more recent evidence, to establish Sativex - a cannabis extract which alleviates symptoms of multiple sclerosis - in over 30 countries.
お知らせ • Mar 21Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Buy Or Sell Opportunity • Mar 14Now 35% overvalued after recent price riseOver the last 90 days, the stock has risen 42% to AU$0.027. The fair value is estimated to be AU$0.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable.
分析記事 • Mar 11Bioxyne Limited (ASX:BXN) Shares Slammed 46% But Getting In Cheap Might Be Difficult RegardlessThe Bioxyne Limited ( ASX:BXN ) share price has softened a substantial 46% over the previous 30 days, handing back much...
お知らせ • Jan 23Bioxyne Limited Upgrades Revenue Guidance for the Year Ended 30 June 2025Bioxyne Limited advised that its upgraded Revenue forecast for the year ended 30 June 2025 is increased to $25,000,000.
お知らせ • Oct 04Bioxyne Limited, Annual General Meeting, Nov 21, 2024Bioxyne Limited, Annual General Meeting, Nov 21, 2024.
Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.64m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.66m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 23Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 18Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
New Risk • Apr 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Share price has been highly volatile over the past 3 months (23% average weekly change). Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Market cap is less than US$10m (AU$15.2m market cap, or US$9.86m).
お知らせ • Nov 17Bioxyne Limited Announces Retirement of N H Chua as DirectorBioxyne Limited announced that Mr. N H Chua has retired from the Board following the Annual General Meeting that was held 17 November 2023. Sam Watson will continue as sole Chief Executive Officer and Managing Director.
お知らせ • Oct 05Bioxyne Limited, Annual General Meeting, Nov 17, 2023Bioxyne Limited, Annual General Meeting, Nov 17, 2023, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)Full year 2023 results: AU$0.001 loss per share (in line with FY 2022). Revenue: AU$5.30m (up AU$4.84m from FY 2022). Net loss: AU$1.94m (loss widened 293% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0.002 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0.002. Revenue: AU$5.34m (up 115% from FY 2022). Net loss: AU$1.94m (loss widened AU$1.70m from FY 2022).
New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$2.3m revenue, or US$1.5m). Market cap is less than US$100m (AU$22.8m market cap, or US$14.6m).
お知らせ • May 24Bioxyne Limited Appoints Jason Hine as DirectorBioxyne Limited announced that the appointment of Jason Hine as director of the company with effect from May 19, 2023.
お知らせ • May 23Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd.Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals. On March 20, 2023, Bioxyne executed the long form Sale and Purchase Agreement with BLS’ majority shareholders. Completed due diligence confirms the synergies between the Bioxyne and BLS. The Bioxyne and BLS have commenced formulating a combined business development growth strategy for post-acquisition. Other conditions precedent to completion include, The remaining minority BLS shareholders acceding as parties to the SPA, New employment agreements for key BLS employees, including appropriate restraints and No material adverse change occurring in relation to Breathe Life Sciences. BXN and BLS will work together, in good faith, to satisfy the remaining conditions precedent by May 31, 2023 to implement the proposed transaction. If the conditions precedent are not satisfied (or waived) by this date, then unless the Long Stop Date is extended by agreement, either party may terminate the SPA and the proposed transaction. As of May 5, 2023, Bioxyne received shareholder approval for the acquisition of BLS.Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd on May 22, 2022. Bioxyne has completed the acquisition of Breathe Life Sciences following shareholder approval, due diligence and the satisfaction of all conditions precedent. BLS's Sam Watson (Chief Executive Officer) and Jason Hine (Chief Operating Officer) will be appointed to the Board of Directors.
Reported Earnings • Feb 24First half 2023 earnings releasedFirst half 2023 results: Revenue: AU$1.28m (down 9.9% from 1H 2022). Net income: AU$23.2k (up 409% from 1H 2022). Profit margin: 1.8% (up from 0.3% in 1H 2022). The increase in margin was driven by lower expenses.
お知らせ • Dec 21Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals.
お知らせ • Dec 20Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive OfficerBioxyne Limited announced joining of Mr. Sam Watson the board as Joint Chief Executive Officer.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 24Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million.Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited (ASX:BXN) for $1 million on October 24, 2022. The Direct Selling business comprises of Bioxyne International Pty Limited, Bioxyne International (NZ) Limited, Bioxyne International Sdn Bhd, PT Gamata Utama, Global Treasure New Zealand Limited and New Zealand Nutritional Research Limited.
お知らせ • Oct 04Bioxyne Limited, Annual General Meeting, Oct 28, 2022Bioxyne Limited, Annual General Meeting, Oct 28, 2022, at 14:00 AUS Eastern Standard Time.
Reported Earnings • Oct 02Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)Full year 2022 results: EPS: AU$0 (improved from AU$0.001 loss in FY 2021). Revenue: AU$2.48m (up 13% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 31Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)Full year 2022 results: EPS: AU$0 (up from AU$0.001 loss in FY 2021). Revenue: AU$2.52m (up 14% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Board Change • Jun 24No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Jun 08Bioxyne Limited Announces Board ChangesBioxyne Limited announced that Mr. Patrick Ford, after serving the company as a director for 17 years, including as chairman of thecompany between 2008 and 2012, has advised the board that Patrick will retire on 30 June 2022. Mr. Guy Robertson, company secretary, will be appointed an executive director, on 30 June 2022. Mr. Robertson is a chartered accountant and is currently a director of Hastings Technology Metals Ltd, Artemis Resources Limited, Metal Bank Limited and Greentech Metals Limited. Ms Rachel Qian, the group's financial controller, will be appointed assistant company secretary, with effectfrom 30 June 2022. Ms Qian has a B.Com, master of accounting (Macquarie), is CPA qualified and is member of the Governance Institute of Australia.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 24First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: EPS: AU$0 (up from AU$0.001 loss in 1H 2021). Revenue: AU$1.42m (up 13% from 1H 2021). Net income: AU$4.6k (up AU$289.2k from 1H 2021). Profit margin: 0.3% (up from net loss in 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 04Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.20m (down 5.6% from FY 2020). Net loss: AU$495.7k (loss narrowed 16% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.22m (down 4.3% from FY 2020). Net loss: AU$425.7k (loss narrowed 28% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Oct 03Full year earnings released - AU$0.00093 loss per shareOver the last 12 months the company has reported total losses of AU$593.1k, with losses narrowing by 53% from the prior year. Total revenue was AU$2.32m over the last 12 months, up 5.4% from the prior year.
